1. There was a risk that engineered bacteria could survive and replicate outside the body, potentially causing environmental harm if they were excreted and entered natural ecosystems.
2. Should the engineered bacteria migrate from the nasal cavity to the lower respiratory tract, they could potentially trigger infections or other detrimental effects, attributable to their engineered characteristics.
3. When engineered probiotics, intended for human application, do trigger undesirable clinical risks—albeit with a minuscule probability, what measures can be promptly implemented to curb these risks?
4. The practicality of our design must also consider the stability and safety of the engineered bacteria during transportation and storage, as well as their compatibility with potential delivery methods.
